Amyris racks up $41.8M for renewable biofuels
Amyris Biotechnologies, one of the most generously-funded startups using microorganisms to produce synthetic biofuels, has added to its third round of funding, taking it from $24.7 million to $41.8 million. But Amyris is not going to stop till it hits its $60 million target, hopefully later this fall, it says. Achieving this amount would boost its total capital raised to more than $165 million (to put this in context, it’s lead competitors LS9 and Coskata… Continue Reading
Amyris takes $24.7M for renewable biofuels
Amyris Biotechnologies, one of the best-funded companies deriving biofuels from synthetic microorganisms, has raised $24.75 million of a targeted $62 million third round of venture financing, according to a regulatory filing with the Securities and Exchange Commission. The Emeryville, Calif. company has raised an impressive $120 million before now.
Both Khosla Ventures and Kleiner Perkins Caufield & Byers have invested in Amyris — also setting it apart as one of the companies to watch in the… Continue Reading
Life sciences briefing: Wednesday, Feb. 6, 2008
TODAY’S HEADLINES:
H-P “great-grandchild” Alverix raises $7.7M for portable diagnostic devices (release)
Moksha8 takes in $39M to commercialize drugs for Asia (peHUB)
Dynogen Pharma goes public, gets $98M in reverse merger (release)
EKR Thera raises funds, pays up to $170M to “reacquire” PDL BioPharma drug (release))
R4 Vascular receives $4.4M for vascular-access devices (VentureWire)
Medical tube and syringe maker Amsino Medical sells stake to Baring PE Asia (release)
Implantable-diagnostic maker Transoma Medical postpones IPO (IPOhome)
H-P “great-grandchild” Alverix raises $7.7M for portable… Continue Reading
Alder Bio and its yeast-produced antibodies take in $40M
Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.
Alder develops antibody-based drugs for inflammation and autoimmune disease. The company’s lead candidate, ALD518, is currently in clinical trials as a treatment for rheumatoid arthritis and cancer, although neither Alder’s Web site nor its statement disclose when the drug began human tests.
Alder’s work… Continue Reading